Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II Clinical Trial Evaluating the Combination of Onapristone With Anastrozole for Women With Refractory Hormone Receptor Positive Endometrial Cancer

NCT04719273 is registered in ClinicalTrials.gov with Thomas Jefferson University as lead sponsor.

NCT NCT04719273
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04719273 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II Clinical Trial Evaluating the Combination of Onapristone With Anastrozole for Women With Refractory Hormone Receptor Positive Endometrial Cancer
Lead sponsor
Thomas Jefferson University
Phase
Phase 2
Overall status
Completed
Start date
January 28, 2021
Completion date
December 17, 2025
Enrollment
14 (actual)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

refractory endometrial adenocarcinoma, refractory endometrial carcinoma, refractory endometrial clear cell adenocarcinoma, refractory endometrial endometrioid adenocarcinoma, refractory endometrial mixed cell adenocarcinoma, refractory endometrial serous adenocarcinoma, refractory endometrial undifferentiated carcinoma